Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ciclesonide.

Neil A Reynolds1, Lesley J Scott

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|February 24, 2004
PubMed
Summary
This summary is machine-generated.

Ciclesonide, an inhaled corticosteroid, demonstrated efficacy comparable to budesonide in improving lung function and asthma symptoms. It was well-tolerated and did not suppress adrenal function in studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Medicine

Background:

  • Ciclesonide is an inhaled corticosteroid (ICS) administered via a hydrofluoroalkane metered-dose inhaler.
  • It is converted to its active metabolite, desisobutyryl-ciclesonide, within the lungs, minimizing systemic exposure and effects on endogenous cortisol.

Purpose of the Study:

  • To evaluate the efficacy and safety of inhaled ciclesonide compared to budesonide in patients with asthma.
  • To assess the impact of ciclesonide on lung function, asthma symptoms, rescue medication use, and adrenal function.

Main Methods:

  • Two 12-week randomized studies compared ciclesonide (80 or 320 microg once daily) with budesonide (400 microg/day) for lung function (FEV1, FVC) and asthma control.
  • A separate randomized, double-blind study assessed lung function in patients on high-dose ICS.

Related Experiment Videos

  • Biochemical markers of adrenal function were monitored in 52-week studies.

    • Main Results:

    • Ciclesonide (80 or 320 microg) was at least as effective as budesonide (400 microg) in improving FEV1 and FVC.
    • Ciclesonide 320 microg showed significantly greater efficacy than budesonide 400 microg in one study.
    • Both doses of ciclesonide improved asthma symptom scores and reduced rescue medication use similarly to budesonide.
    • Ciclesonide did not suppress biochemical markers of adrenal function over 52 weeks, unlike budesonide which showed a significant decrease in peak expiratory flow in one study.

    Conclusions:

    • Inhaled ciclesonide is an effective treatment for asthma, offering comparable or superior efficacy to budesonide in improving lung function and symptom control.
    • Ciclesonide demonstrates a favorable safety profile, with no observed suppression of adrenal function in 52-week studies.
    • Long-term systemic effects of ciclesonide require further investigation.